As FGFR3 alteration was still a widely acknowledged favorable prognostic factor, a total of 3,724 DEGs were subsequently identified between 42 FGFR3-altered and 240 wild-type BC patient samples from the TCGA-BC cohort, of which 962 were upregulated and 2,762 were downregulated (fold change > 1.5, adjusted p-value < 0.01, Supplementary Figure 2). This evidence concerns the gene FGFR3 and breast cancer.